J Asthma:秋天花粉诱导的过敏性鼻炎中,血清特异性lgE水平与哮喘相关性研究

2018-04-27 AlexYang MedSci原创

艾草和葎草花粉在中国北方是2中最为重要的秋季过敏过敏原。在2001年的代表性数据表明了过敏性鼻炎总是领先或者是同时和中国北方的秋季花粉过敏病人哮喘发生。最近,有研究人员利用代表性的数据调查了血清特异性lgE (slgE)水平与葎草和/或艾草花粉的相关性,时间点事秋季花粉诱导的过敏性鼻炎患者哮喘开始时。研究包括了1096名秋季花粉病患者,并且进行了面对面交谈和对葎草和艾草的slgE测试,阐释和记录了

艾草和葎草花粉在中国北方是2中最为重要的秋季过敏过敏原。在2001年的代表性数据表明了过敏性鼻炎总是领先或者是同时和中国北方的秋季花粉过敏病人哮喘发生。最近,有研究人员利用代表性的数据调查了血清特异性lgE (slgE)水平与葎草和/或艾草花粉的相关性,时间点事秋季花粉诱导的过敏性鼻炎患者哮喘开始时。

研究包括了1096名秋季花粉病患者,并且进行了面对面交谈和对葎草和艾草的slgE测试,阐释和记录了过敏性鼻炎和哮喘的时间序列。slgE测试中,1013名患者对葎草和/或艾草花粉呈现阳性反应。在秋季花粉诱导的过敏性鼻炎中,研究人员利用多项逻辑斯蒂回归和生存分析用来探究slgE水平在哮喘进展中潜在的应用。研究发现,1013名具有对对葎草和/或艾草花粉呈现阳性反应的参与者中,563(55.6%)名参与者具有过敏性鼻炎历史,并且先于或者同时与哮喘发生。450名(44.4%)只患有过敏性鼻炎。在控制了性别、年龄和过敏性鼻炎起始、父母哮喘后,对葎草和艾草来说,研究发现发展为哮喘风险的增加随着slgE水平的增加而增加(P<0.05)。在Kaplan-Meier分析中,对葎草和艾草lgE 5-6级别水平能够增加哮喘发展风险(P<0.05)。

最后,研究人员指出,秋季花粉诱导的过敏性鼻炎总能够与季节性哮喘共存。当slgE水平更高时,哮喘的发生将会更加显著。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-10-26 skhzy
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-29 HNYYM
  8. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-28 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1837505, encodeId=1c62183e50597, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 13 12:06:00 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977124, encodeId=225e19e712460, content=<a href='/topic/show?id=0081289832' target=_blank style='color:#2F92EE;'>#asthma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2898, encryptionId=0081289832, topicName=asthma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Fri Oct 26 00:06:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046958, encodeId=33722046958ec, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Feb 08 00:06:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899213, encodeId=3b2718992137a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Oct 10 15:06:00 CST 2018, time=2018-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1711465, encodeId=daad1e114651a, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Sun Mar 10 00:06:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396419, encodeId=71d21396419d5, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539206, encodeId=02cf1539206eb, content=<a href='/topic/show?id=6505108534a' target=_blank style='color:#2F92EE;'>#lgE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10853, encryptionId=6505108534a, topicName=lgE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=beb613117181, createdName=HNYYM, createdTime=Sun Apr 29 11:06:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310098, encodeId=f23831009814, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:03 CST 2018, time=2018-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310092, encodeId=efe73100928d, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Sat Apr 28 12:09:16 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-28 wzb521zf

    一起学习学习

    0

相关资讯

Int Arch Otorhinolaryngol:白介素-33水平在过敏性鼻炎患者中免疫治疗治疗效果中的作用研究

过敏性鼻炎(AR)影响了多达40%的人口比例,并且能够导致鼻痒症、充血、打喷嚏和流清鼻涕。最近,有研究人员在患有AR的病人中,进行了旨在评估花粉免疫治疗(IT)前后临床症状和血清白介素(IL)-33的水平变化的情况。研究人员在10名非过敏性的健康对照和45名患有AR的病人中确定了总症状得分和总免疫球蛋白E(lgE)以及IL-33。参与的病人被分成3个小组:GI组(病人没有进行IT),GII(病人进

Int Arch Allergy Immunol:气道变应性炎症患者中,第二组先天性淋巴细胞的增加与嗜酸性粒细胞相关

辅助T(Th2)类型响应被认为是过敏性气道疾病的本质,包括了哮喘和过敏性鼻炎(AR)。然而,有研究表明过敏性气道炎症同样依赖于先天免疫,并且与第二组先天性淋巴细胞(ILC2s)密切相关。最近,有研究人员在哮喘患者、哮喘和过敏性鼻炎患者以及健康个体中评估了ILC2的水平,并且尝试分析调查了临床数据和ILC2水平之间的关系。研究发现,哮喘患者和患有哮喘的过敏性鼻炎病人与健康对照相比,具有更低水平的IL

Asian Pac J Allergy Immunol:过敏性鼻炎的空气净化器治疗效果研究

随着过敏性鼻炎流行度的增加,室内环境管理的利用得到了越来越多的关注。最近,有研究人员评估了空气净化器作为过敏性鼻炎治疗手段的效果。研究包括了32名(年龄在25±13.5岁)且诊断为过敏性鼻炎的参与者,并且将HEPA空气净化器放置在他们的卧室4个月。在干预之前和干预的每个月,研究人员利用真空吸尘器和灰尘搜集器对灰尘样本进行搜集,并且用于过敏原种类的评估。另外,研究人员还通过静态灰尘搜集器通过沉降对灰

Immunotherapy:单磷酰脂质A辅助的特异性免疫治疗在患有花粉过敏患者中的长期影响研究

单磷酰脂质A辅助的超短疗程花粉免疫治疗(MPL)与传统的过敏原特异性免疫治疗(AIT)相比是具有吸引力的。然而,MPL-AIT的长期治疗效果还没有进行评估。最近,有研究人员在对花粉过敏的68名过敏性鼻炎患者中(年龄16.75 ±5.3岁 )进行了调查。研究包括了3个小组,组1为21名对照,组2为19名完成AIT的病人,组3为28名具有AIT治疗和治疗终止的病人。研究发现,与没有AIT治疗的对照相比

Asian Pac J Allergy Immunol:患有或不患有过敏性鼻炎的哮喘儿童中,Th17细胞调控的免疫应答比较

最近,有研究人员在患有或者不患有过敏性鼻炎的哮喘儿童中,调查了Th17细胞调控的免疫应答是否具有差异。研究人员在儿童中进行了一个案例-对照比较试验,其中包括67名哮喘(AS)儿童,50儿童患有过敏性鼻炎,52名儿童同时患有AS和AR(ASR),25名为传染性鼻炎(IR)和55名健康对照(HC)。研究人员使用的技术包括流式细胞仪、酶联免疫吸附试验等。研究发现,组内比较阐释了Th17细胞在ASR组中水

Am J Otolaryngol:鼻中隔成形术后,过敏性鼻炎对鼻塞治疗结果的影响

为了评估是否过敏性鼻炎(AR)的诊断会对开放式鼻中隔成形术(OSR)的外科手术治疗产生影响以及调查是否OSR是否能够对过敏性鼻炎患者或者不患有过敏性鼻炎的患者提供同样水平的生活质量的提高。研究人员在2008年到2015年进行了相关的回顾性研究,研究包括了646名经历了开放式鼻中隔成形术的病人。研究人员对满足入选条件的307名患者利用鼻塞症状评估(NOSE)模块进行了术前和术后生活质量(QoL)的测